People · Operator
Named in public records as an officer, director or promoter · active 2022–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ribon Therapeutics, Inc. | — | Biotechnology | Series B | $119.1M | $343.2M | 2022 |
| RYNE Biotechnology Inc. | — | Biotechnology | Series B | $33.0M | $248.2M | 2024 |
| Remix Therapeutics, Inc. | — | Biotechnology | Series A | $13.7M | $93.0M | 2023 |
| NILO Therapeutics, Inc. | — | Biotechnology | Series A | $9.6M | $49.3M | 2024 |
Jeff Goater at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jeff Goater on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jonathan Root | 1 | 16 |
| Kevin Bitterman | 1 | 15 |
| Peter Smith | 1 | 9 |
| Cameron Wheeler | 1 | 9 |
| Tim Kutzkey | 1 | 7 |
| Jeff Jonas | 1 | 5 |
| Carter Cliff | 1 | 4 |
| Paul Brannelly | 1 | 4 |
| Emma Reeve | 1 | 4 |
| Michael Rome | 1 | 3 |
| Eyal Lifschitz | 1 | 3 |
| Matthew Patterson | 1 | 3 |
| LAURA BRASS | 1 | 3 |
| Robert Gagnon | 1 | 2 |
| Gary Sutton | 1 | 2 |
| William M. Harrington | 1 | 2 |
| Laurence Lasky | 1 | 2 |
| David Fallace | 1 | 2 |
| Emma M. Reeve | 1 | 1 |
| Jodie M. Morrison | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.